Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

DOI Web Site Web Site 被引用文献3件
  • Ursula Amstutz
    University Institute of Clinical Chemistry, Inselspital Bern University Hospital University of Bern Bern Switzerland
  • Linda M. Henricks
    Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology the Netherlands Cancer Institute Amsterdam the Netherlands
  • Steven M. Offer
    Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic Rochester Minnesota USA
  • Julia Barbarino
    Department of Biomedical Data Science Stanford University Stanford California USA
  • Jan H.M. Schellens
    Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology the Netherlands Cancer Institute Amsterdam the Netherlands
  • Jesse J. Swen
    Department of Clinical Pharmacy & Toxicology Leiden University Medical Center Leiden the Netherlands
  • Teri E. Klein
    Department of Biomedical Data Science Stanford University Stanford California USA
  • Howard L. McLeod
    DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
  • Kelly E. Caudle
    Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
  • Robert B. Diasio
    Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic Rochester Minnesota USA
  • Matthias Schwab
    Dr Margarete Fischer‐Bosch‐Institute of Clinical Pharmacology Stuttgart Germany

説明

<jats:p>The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (<jats:italic>DPYD</jats:italic>) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5‐fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology,<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#cpt911-bib-0001" /> as well as analyses of cost‐effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC<jats:sup>®</jats:sup>) guidelines consider the situation of patients for which genotype data are already available<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#cpt911-bib-0002" /> (updates available at <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/">https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/</jats:ext-link>).</jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ